Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

OncoZenge

5.36

 

SEK

 

+6.56 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+6.56%
+19.78%
-14.1%
+42.93%
+25.97%
+53.14%
+85.15%
-
-56.2%

OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Read more
Market cap
62.78M SEK
Turnover
442.98K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21.8
2025

Interim report Q2'25

20.11
2025

Interim report Q3'25

All
Press releases
ShowingAll content types
Regulatory press release5/30/2025, 6:45 AM

OncoZenge AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment

OncoZenge
Press release5/15/2025, 9:35 AM

Redeye: OncoZenge Q1 - Pieces falling into place

OncoZenge
Regulatory press release5/12/2025, 7:30 AM

OncoZenge AB: OncoZenge: Investor Receives NDRC Approval

OncoZenge

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/25/2025, 6:30 AM

OncoZenge AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment

OncoZenge
Press release4/11/2025, 8:15 AM

OncoZenge AB: OncoZenge enters licensing agreement with Avernus Pharma for BupiZenge™ in the GCC Region

OncoZenge
Regulatory press release4/11/2025, 7:45 AM

OncoZenge AB: OncoZenge receives milestone payment from Molteni

OncoZenge
Press release4/4/2025, 8:00 AM

OncoZenge AB: OncoZenge Strengthens Phase 3 Sponsor Team for Regulatory Affairs

OncoZenge
Press release4/2/2025, 2:40 PM

OncoZenge AB: OncoZenge presents BupiZenge™ Phase 3 abstract at leading supportive cancer care conference in the US in June

OncoZenge
Regulatory press release3/28/2025, 7:00 AM

OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

OncoZenge
Press release3/4/2025, 3:00 PM

OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™

OncoZenge
Regulatory press release1/27/2025, 6:00 PM

OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues

OncoZenge
Press release1/16/2025, 2:02 PM

OncoZenge AB files PCT patent application for BupiZenge™

OncoZenge
Regulatory press release1/13/2025, 4:30 PM

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

OncoZenge
Press release11/26/2024, 10:30 AM

Redeye: OncoZenge - Down, but not out

OncoZenge
Press release11/18/2024, 9:27 AM

Redeye: OncoZenge Q3 2024 - Approaching lift-off

OncoZenge
Press release10/31/2024, 8:25 AM

Redeye: Redeye Initiates Coverage of OncoZenge

OncoZenge
Regulatory press release10/18/2024, 8:00 AM

OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa

OncoZenge
Press release6/4/2024, 3:15 PM

OncoZenge AB: OncoZenge participates in MASCC cancer care conference June 27-29

OncoZenge
Press release4/26/2024, 12:00 PM

OncoZenge AB: OncoZenge Appoints Anna Asplind as Phase 3 Program Manager

OncoZenge
Press release4/25/2024, 12:40 PM

OncoZenge AB: OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

OncoZenge
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team